Booth No.5Q-10
CategoryOutsourcing

Ind-Swift Laboratories Ltd.

Booth No.:5Q-10
Category:Outsourcing
Company Information
Email: sharma.ekta@indswiftlabs.com TEL: +91-11-4705-1214 Address: 110025
Ind-Swift Laboratories Ltd. No. 3 H (Part 1), 3rd Floor, Uppal Plaza M6, District Centre, Jasola, New Delhi INDIA
URL: https://www.indswiftlabs.com/
Contact in Japan
Japan agent: Ind-swift Laboratories Limited
Headquartered in Chandigarh, India, Ind-Swift Laboratories Ltd today is a global manufacture of Apis, Intermediates. We are trusted API partner for many leading organizations both in generic and innovative domains. We have successful track record, persistent quality, wide therapeutic range to offer on grounds of our world class manufacturing facilities and regulatory expertise. Today, Ind-Swift Laboratories Ltd. is a significant player in manufacturing APIs towards Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor. We also hold global leadership positions in the Macrolide Antibiotic segment.

Company information

Address 110025
Ind-Swift Laboratories Ltd. No. 3 H (Part 1), 3rd Floor, Uppal Plaza M6, District Centre, Jasola, New Delhi INDIA
TEL +91-11-4705-1214
URL https://www.indswiftlabs.com/
Email sharma.ekta@indswiftlabs.com
Product Classification FEXOFENADINE HCl
ATORVASTATIN CALCIUM
ROPINIROLE HCl
DONEPEZIL HCl FORM III
MIRABEGRONNew
IBRUTINIBNew
RISEDRONATE SODIUM
ELTROMOBOPAGNew
SAXAGLIPTINNew
SITAGLIPTINNew
LISDEXAMFETAMINE DIMESYLATENew
LETROZOLE
QUETIAPINE
TEMOZOLOMIDENew
DONEPEZIL BASENew
CLOPIDOGREL BISULPHATE FORM IINew

Contact in Japan

Japan Agent Ind-swift Laboratories Limited

Product introduction

FEXOFENADINE HClATORVASTATIN CALCIUMROPINIROLE HClDONEPEZIL HCl FORM IIIMIRABEGRONNewIBRUTINIBNewRISEDRONATE SODIUMELTROMOBOPAGNewSAXAGLIPTINNewSITAGLIPTINNewLISDEXAMFETAMINE DIMESYLATENewLETROZOLEQUETIAPINETEMOZOLOMIDENewDONEPEZIL BASENewCLOPIDOGREL BISULPHATE FORM IINew